EV-PURE is under clinical development by Vitti Labs and currently in Phase I for Premature Ovarian Failure. According to GlobalData, Phase I drugs for Premature Ovarian Failure does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EV-PURE LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EV-PURE is under development for the treatment of chronic obstructive pulmonary disease (COPD), osteoarthritis, traumatic brain injury, Crohn's disease, premature ovarian failure, COVID-19 associated acute respiratory distress syndrome and Alzheimer's disease. The therapeutic candidate comprises of placental derived exosomes and is administered by intravenous route.
It was also under development for COVID induced pulmonary fibrosis.
Vitti Labs overview
Vitti Labs is focused on life science research, development and manufacturing. Vitti Labs is headquartered in Liberty, Missouri, the US.
For a complete picture of EV-PURE’s drug-specific PTSR and LoA scores, buy the report here.